Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

A Study of Single and Multiple Subcutaneous or Intravenous Doses of ADX-001 in Healthy Adults to Assess Safety, Effects, and Immune Response

2 novembre 2026 mis à jour par: Adaxion Therapeutics

A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of Subcutaneous and Intravenous ADX-001 in Healthy Adult Participants

This is a phase 1, randomized, double-blind, placebo-controlled, single and multiple ascending dose study to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of subcutaneous and intravenous ADX-001 in healthy adult participants

Aperçu de l'étude

Statut

Recrutement

Les conditions

Description détaillée

ADX-001 is a new investigational medicine being developed to treat inflammatory diseases, such as inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, and certain rheumatic diseases, such as psoriatic arthritis.

The purpose of this study is to evaluate the safety and tolerability of ADX-001 in healthy adult volunteers. The study will also examine how the body processes the medicine, how the medicine affects the immune system, and whether the body develops antibodies against the medicine. The results of this study will help determine appropriate doses and dosing schedules for future studies in patients with inflammatory diseases.

Type d'étude

Interventionnel

Inscription (Estimé)

88

Phase

  • La phase 1

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

    • South Australia
      • Adelaide, South Australia, Australie, 5000
        • Recrutement
        • CMAX Clinical Research

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 55 ans (Adulte)

Accepte les volontaires sains

Oui

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Provide informed consent - Be willing and able to sign a consent form after understanding the study and before any study-related procedures are performed.
  • Age - Be a healthy adult male or female aged 18 to 55 years.
  • Body weight and BMI - Have a Body Mass Index (BMI) between 18.0 and 32.0 kg/m². Weigh more than 50 kg and less than 120 kg.
  • For women who can become pregnant - Have a negative pregnancy test before participating.
  • Use highly effective birth control during the study and for 15 months after the last study dose.

Exclusion Criteria:

You cannot participate in this study if any of the following apply to you:

  1. Medical Conditions

    • You have a serious or ongoing health condition affecting the heart, lungs, liver, kidneys, digestive system, hormones, nervous system, immune system, or mental health.
    • You have a history of severe allergic reactions, anaphylaxis, or are allergic to the study drug or its ingredients.
  2. Infections

    • You test positive for HIV, hepatitis B, or hepatitis C.
    • You have tuberculosis (TB), a history of TB, recent close contact with someone who has active TB, or a positive TB screening test.
    • You test positive for COVID-19 before receiving the study drug.
    • You have an active or long-term infection requiring treatment.
    • You have needed antibiotics or other anti-infective treatment within the last month.
    • You were hospitalized or required intravenous (IV) treatment for an infection within the last 3 months.
    • You have a history of certain recurring infections, such as shingles (herpes zoster).
    • You have a fever higher than 37.7°C during screening or within 7 days before dosing.
    • In some cases, minor abnormalities may be accepted if the study doctor considers them not clinically important.

4. Heart and Blood Pressure Problems 5. Previous Medications or Treatments

  • You have previously received medicines that target TNFα or IL-23.

  • You have received other biologic medicines within the last 6 months.

  • You have used medicines that significantly suppress the immune system within the required washout period.

  • You have recently used prescription or over-the-counter medications that could affect study results.

  • You received a live vaccine within the last 12 weeks or any other vaccine within the last 4 weeks.

  • You donated blood, plasma, or platelets too recently before joining the study.

    6. Alcohol or Drug Use. 7. Pregnancy and Reproductive Considerations

  • You are pregnant, breastfeeding, or planning to become pregnant during the study period.

  • You are unwilling to use the required birth control methods.

    8. Participation in Other Research Studies

  • You have recently participated in another clinical trial involving an investigational drug or device.

  • You have previously participated in this study.

    9. Ability to Participate

  • You are unable to understand the study requirements or provide informed consent.

  • You are unable or unwilling to follow study procedures and visit schedules.

    10. Conflict of Interest

  • You are an employee of the study sponsor or investigator, or an immediate family member of one.

    11. Other Safety Concerns

  • The study doctor believes that participating could put your health at risk, prevent you from completing the study, or affect the reliability of the study results.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Double

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: SAD Cohort 1-5

ADX-001 administered as a single dose according to the assigned cohort and route of administration (SC or IV).

ADX-001 administered every 4 weeks (Q4W) for a total of 4 doses according to the assigned cohort and route of administration (SC or IV).

Matching placebo administered by SC injection or IV infusion according to the route and dosing schedule of the assigned cohort.

Expérimental: MAD Cohort 6-9

ADX-001 administered as a single dose according to the assigned cohort and route of administration (SC or IV).

ADX-001 administered every 4 weeks (Q4W) for a total of 4 doses according to the assigned cohort and route of administration (SC or IV).

Matching placebo administered by SC injection or IV infusion according to the route and dosing schedule of the assigned cohort.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Délai
Incidence and severity of Treatment Emergent Adverse Events (TEAEs) of single and multiple doses of ADX-001 administered by subcutaneous and intravenous injection
Délai: From first dose through Day 365 for participants receiving a single dose and through Day 505 for participants receiving multiple doses.
From first dose through Day 365 for participants receiving a single dose and through Day 505 for participants receiving multiple doses.

Mesures de résultats secondaires

Mesure des résultats
Délai
PK Parameters peak concentration (Cmax) - SAD
Délai: Pre-dose on Day 1 through Day 365
Pre-dose on Day 1 through Day 365
PK Parameters peak concentration (Cmax) - MAD
Délai: Pre-dose on Day 1 through Day 87
Pre-dose on Day 1 through Day 87
Area under the concentration-time curve (AUC0-t) - SAD
Délai: Pre-dose on Day 1 through Day 365
Pre-dose on Day 1 through Day 365
Area under the concentration-time curve (AUC0-t) - MAD
Délai: Pre-dose on Day 1 through Day 87
Pre-dose on Day 1 through Day 87
Terminal elimination half-life (t1/2) - SAD
Délai: Pre-dose on Day 1 through Day 365
Pre-dose on Day 1 through Day 365
Terminal elimination half-life (t1/2) - MAD
Délai: Pre-dose on Day 1 through Day 87
Pre-dose on Day 1 through Day 87
Clearance (CL) - SAD
Délai: Pre-dose on Day 1 through Day 365
Pre-dose on Day 1 through Day 365
Clearance (CL) - MAD
Délai: Pre-dose on Day 1 through Day 87
Pre-dose on Day 1 through Day 87
Volume of distribution (Vz) - SAD
Délai: Pre-dose on Day 1 through Day 365
Pre-dose on Day 1 through Day 365
Volume of distribution (Vz) - MAD
Délai: Pre-dose on Day 1 through Day 87
Pre-dose on Day 1 through Day 87
Serum concentrations of free CD22L- SAD
Délai: Pre-dose on Day 1 through Day 365
Pre-dose on Day 1 through Day 365
Serum concentrations of free CD22L- MAD
Délai: Pre-dose on Day 1 through Day 87
Pre-dose on Day 1 through Day 87
Incidence of treatment-emergent anti-drug antibodies (ADA)
Délai: From Day 14 through Day 112 after a single dose, and through 56 days after the final dose following multiple doses
From Day 14 through Day 112 after a single dose, and through 56 days after the final dose following multiple doses
Maximum observed serum concentration (Cmax) of ADX-001 by ADA status
Délai: From Day 14 through Day 112 after a single dose, and through 56 days after the final dose following multiple doses
From Day 14 through Day 112 after a single dose, and through 56 days after the final dose following multiple doses
Minimum observed serum concentration (Cmin) of ADX-001 by ADA status
Délai: From Day 14 through Day 112 after a single dose, and through 56 days after the final dose following multiple doses
From Day 14 through Day 112 after a single dose, and through 56 days after the final dose following multiple doses
Area under the serum concentration-time curve (AUC0-last) of ADX-001 by ADA status
Délai: From Day 14 through Day 112 after a single dose, and through 56 days after the final dose following multiple doses
From Day 14 through Day 112 after a single dose, and through 56 days after the final dose following multiple doses
Area under the serum concentration-time curve over the dosing interval (AUCτ) of ADX-001 by ADA status
Délai: From Day 14 through Day 112 after a single dose, and through 56 days after the final dose following multiple doses
From Day 14 through Day 112 after a single dose, and through 56 days after the final dose following multiple doses
Clearance (CL) of ADX-001 by ADA status
Délai: From Day 14 through Day 112 after a single dose, and through 56 days after the final dose following multiple doses
From Day 14 through Day 112 after a single dose, and through 56 days after the final dose following multiple doses
Terminal elimination half-life (t½) of ADX-001 by ADA status
Délai: From Day 14 through Day 112 after a single dose, and through 56 days after the final dose following multiple doses
From Day 14 through Day 112 after a single dose, and through 56 days after the final dose following multiple doses
Incidence of treatment-emergent adverse events by ADA status
Délai: From Day 14 through Day 112 after a single dose, and through 56 days after the final dose following multiple doses
From Day 14 through Day 112 after a single dose, and through 56 days after the final dose following multiple doses

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

20 octobre 2026

Achèvement primaire (Estimé)

29 juillet 2027

Achèvement de l'étude (Estimé)

14 décembre 2028

Dates d'inscription aux études

Première soumission

2 octobre 2026

Première soumission répondant aux critères de contrôle qualité

11 octobre 2026

Première publication (Réel)

15 octobre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

4 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

2 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • ADX-001-CLN-01

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner